Uiuce bus model

From 2013.igem.org

(Difference between revisions)
 
(58 intermediate revisions not shown)
Line 18: Line 18:
body{
body{
   color: #34495e;
   color: #34495e;
 +
  width: 1000px;
 +
  margin: 0 auto;
}
}
#bodyContent h1, #bodyContent h2{
#bodyContent h1, #bodyContent h2{
Line 66: Line 68:
/*the nav settings
/*the nav settings
----------------------------------------------- */
----------------------------------------------- */
 +
ul.navbar-nav{margin: 0 -35px 25px 0;float: right;}
.navbar-inverse .navbar-nav>.open>a, .navbar-inverse .navbar-nav>.open>a:hover, .navbar-inverse .navbar-nav>.open>a:focus{
.navbar-inverse .navbar-nav>.open>a, .navbar-inverse .navbar-nav>.open>a:hover, .navbar-inverse .navbar-nav>.open>a:focus{
   color: #1abc9c;
   color: #1abc9c;
Line 348: Line 351:
     <div class="collapse navbar-collapse navbar-ex1-collapse">
     <div class="collapse navbar-collapse navbar-ex1-collapse">
       <ul class="nav navbar-nav pull-right">
       <ul class="nav navbar-nav pull-right">
-
       <li><a href="https://2013.igem.org/Team:UIUC_Entrepreneurs">Home</a></li>
+
       <li><a href="https://2013.igem.org/Team:UIUC_Entrepreneurs"><font size="5"><b>Home</b></font></a></li>
-
     <li><a href="https://2013.igem.org/Uiuce_bus_model">Business Model</a></li>
+
     <li><a href="https://2013.igem.org/Uiuce_bus_model"><font size="5"><b>Business Model</b></font></a></li>
-
       <li><a href="https://2013.igem.org/Uiuce_modulab">ModuLab</a></li>
+
       <li><a href="https://2013.igem.org/Uiuce_modulab"><font size="5"><b>ModuLab</b></font></a></li>
            
            
      
      
Line 360: Line 363:
      
      
       <li class="dropdown">
       <li class="dropdown">
-
                 <a class="dropdown-toggle" data-toggle="dropdown" href="#">About Us<b class="caret"></b></a>
+
                 <a class="dropdown-toggle" data-toggle="dropdown" href="#"><font size="5"><b>About Us</b></font><b class="caret"></b></a>
                 <ul id="menu2" class="dropdown-menu" role="menu" aria-labelledby="dropdownMenu">
                 <ul id="menu2" class="dropdown-menu" role="menu" aria-labelledby="dropdownMenu">
-
                          <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Uiuce_our_mission">Our MIssion</a></li>
 
                           <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Igeme_team">Our Team</a></li>
                           <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Igeme_team">Our Team</a></li>
                           <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Uiuce_advisory_board">Advisory Board</a></li>
                           <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Uiuce_advisory_board">Advisory Board</a></li>
-
                           <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Uiuce_igeme">iGEMe</a></li>
+
                           <li role="presentation"><a role="menuitem" tabindex="-1" href="https://igem.org/Main_Page">iGEM</a></li>
                          
                          
_TOC_             
_TOC_             
Line 375: Line 377:
</div>     
</div>     
<!--the slidershow begin-->
<!--the slidershow begin-->
-
<div class="banner">
+
 
-
      <ul>
+
-
        <li style="background-image: url('https://static.igem.org/mediawiki/2013/e/e8/Smiling_fox.jpg');">
+
-
          <div class="inner">
+
-
         
+
-
         
+
-
           
+
-
          </div>
+
-
        </li>
+
        
        
-
      </ul>
+
   
-
  </div>
+
   <!--the slidershow end-->
   <!--the slidershow end-->
-
 
+
 
-
<div class="container" id="Competitive_Analysis">
+
        <left><h3><b>Business Model</b></h3><hr></left>
-
        <h3><b>Business Model</b></h3><hr>
+
          
          
-
       
+
-
</div>
+
-
<!--iGEME 2012 CODE-->
+
</div>
-
<html xmlns="http://www.w3.org/1999/xhtml">
+
-
<head>
+
-
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
+
-
<link rel="stylesheet" href="css/css.css" type="text/css" />
+
-
<title>Data</title>
+
-
<link href="CSS/css.css" rel="stylesheet" type="text/css" />
+
-
</head>
+
-
<script src="http://ajax.googleapis.com/ajax/libs/jquery/1.7.2/jquery.min.js"></script>
+
<center><font size="3"><b> Business Overview</b></font><br></center>
 +
<p><b>Customer Problem</b></p><br>
 +
<p>The cloning process consists of several individual steps, each with its own equipment and machinery. It is complex, yet still requires a remarkable amount of human intervention. This results in errors, inconsistencies, and an overall delay in meeting significant synthetic biology milestones. Our team seeks to minimize this “human intervention” element by designing, prototyping, and commercializing an automated cloning system.</p><br>
-
<script>
+
<center><img src="https://static.igem.org/mediawiki/2013/e/ec/Uiuce_Igeme_customer_prob.png" width="400" height="294" alt="Pills" /></center><br><br>
-
$(document).ready(function(){
+
<p><b>Our Solution</b></p><br>
-
    $('a').click(function () {
+
<p>Our flagship product, ModuLab, is an automated system designed to optimize cloning, the underlying process of synthetic biology. The ultimate goals of ModuLab are to minimize error, maximize efficiency and provide synthetic biologists with feedback on every stage of the cloning process.</p><br><br><br>
-
        var divname= this.name;
+
-
        $("#"+divname)
+
-
.fadeIn(300)
+
-
.siblings()
+
-
.hide(0);
+
-
    });
+
-
});
+
-
</script>
+
<center><font size="3"><b> Competitive Analysis</b></font><br></center>
-
</head>
+
-
<body>
+
<p><b>Direct Competition</b></p><br>
-
    <div id="dataContainer">
+
<p>Because of the relative youth of synthetic biology, there are currently no products that are able to fully conduct the cloning protocol from start to finish without human intervention. We could, however, experience competition from device manufacturers that produce some of the individual components of our system. As per our own research, the closest product to ModuLab is the Freedom EVO® Expression Workstation produced by Tecan Group Ltd.</p>
-
            <div id="dataSelection">
+
-
                    <li><a name="data0" >Competitive Analysis</a></li>
+
<center><img src="https://static.igem.org/mediawiki/2013/8/82/Uiuce_direct_comp.png" width="720" height="294" alt="Pills" /><br><br></center>
-
               
+
-
                    <li><a name="data2" >Market Penetration Strategy</a></li>
+
-
                    <li><a name="data3" >Marketing Plan</a></li>
+
-
                    <li><a name="data4" >Financial Plan</a></li>
+
-
                    <li><a name="data5" >Risk Analysis</a></li>
+
-
            </div>
+
-
               
+
-
            <div id="dataOverview">
+
-
<center><h2>Competitive Analysis</h2></center>
+
-
<br/>
+
-
<p>Comp an text <br><br><br></p>
+
 +
<p><b>Indirect Competition</b></p>
 +
<p>Indirect competition to the field of synthetic biology as a whole is high, given other technologies that have been around for decades. In the specific niche market within which Vivosynth is positioned, however, such competition is negligible, because of the relative nonexistence of methods to fully automate the cloning protocol.</p><br>
-
<div id="data0" style="display:none">
+
<p><b>Future Competition </b></p>
 +
<p>Future competition will likely come in the form of new advances in robotics and automation that will further optimize cloning.  Vivosynth is uniquely suited to adapting to these new advances because of our close ties to the University of Illinois and our ability to modify our product(s) as and when it needs </p><br>
-
<center><h2>Market Penetration Strategy</h2></center>
+
<p><b> Competitive Advantage</b></p><br>
-
<br/>
+
<p>Our product, ModuLab, would be unique in its ability to conduct the entire cloning protocol from start to finish without human intervention. As far as we know, there are no products capable of doing this. We believe such a product would dramatically increase the rate at which synthetic biology research and manufacturing progresses over the next decade. The product is also unique because it will be able to adapt to automate any lab machinery.</p><br><br>
-
<p>The results covered in this section are of the experiments overviewed in the <a href="https://2012.igem.org/Team:UIUC-Illinois/Project/Design">Design section</a>. Please note that not all planned experiments have been completed or have data ready for disclosure. The data that is complete, that which has been collected and compiled, is listed to the left for their respective experiments.</p>
+
 +
<center><font size="3"><b> Market Analysis</b></font><br></center>
 +
<p><b>Industry Profile</b></p><br>
 +
<p>The global synthetic biology market is estimated to grow to $4.5 billion over the next three years. This is due to major developments in biomedicine, pharmaceutical drug synthesis, energy and environmental research, biomaterials, nanotechnology, and biosecurity. There have been significant investments in the industry by companies such as Amyris Inc, GeneScript, Bayer, and Blue Heron Biotechnologies. Additionally, developments in DNA synthesis and sequencing technologies and bioinformatics have catalyzed the progress of synthetic biology ever since the creation of the first synthetic cell in 2010. Synthetic biology is being recognized around the world as an emerging technology that has the potential to provide solutions to energy and food shortage, pollution, infectious diseases, and even climate change. The following diagram depicts the distribution of the global synthetic biology market share, as of 2011:</p><br><br>
-
</div>
+
<center><img src="https://static.igem.org/mediawiki/2013/4/4c/Uiuce_industrial_prof.png" width="500" height="294" alt="Pills" /><br><br></center>
-
<div id="data1" style="display:none">
+
<p><b>Marketing Strategy</b></p>
 +
<p>Vivosynth will adopt a two-step marketing plan for commercializing ModuLab. It involves the systematic dissemination of our technologies to academic and research institutions at highly discounted rates, followed by the targeted selection of pharmaceutical companies and chemical manufacturers with our final full-price system. Intellectual property protection for our design will be obtained prior to the execution of our sales strategy.<br><br>
-
<center><h2>Mutant PUF Expression Gel</h2></center><br/>
+
Next, the company will look to enter into distribution agreements for the registration and sales of its products in the United States, and eventually foreign countries. These distribution agreements will take the form of contracts with existing manufacturers of biotechnology devices, in order to achieve economies of scale. <br><br>
-
<p> text text </p>
+
Vivosynth will also actively pursue online advertising, advertise our products at biotechnology oriented trade shows, and release a monthly newsletter to keep potential and current customers updated about product developments.<br><br>
-
</div>
+
<center><img src="https://static.igem.org/mediawiki/2013/3/37/Uiuce_marketing.png" width="720" height="294" alt="Pills" /><br><br><br><br></center>
-
<div id="data2" style="display:none">
 
-
<center><h2>Competitive Analysis</h2></center><br/>
+
<center><font size="3"><b> Past and Projected Timeline</b></font><br></center>
 +
<p>Our business model has currently been implemented through the model creation phase. Next steps include cultivating relationships and licensing our technology to existing biotechnology device manufacturers.</p>
-
<img src="https://static.igem.org/mediawiki/2012/d/d2/FixedYFPfltest.png" height=400 width=715>
+
<center><img src="https://static.igem.org/mediawiki/2013/5/5b/Uiuce_timeline.png" width="720" height="294" alt="Pills" /><br><br><br><br><br></center>
-
<br/><br/>
+
-
Where is this?
 
-
<br/><br/>
 
-
As a reference to our aformentioned experimental design predictions. The theoretical results chart is shown here again.
+
<center><font size="3"><b>Financial Plan</b></font><br></center><br><br>
-
<br/><br/>
+
<center><img style="-webkit-user-select: none" src="https://static.igem.org/mediawiki/2013/9/9f/Uiuce_table_edit.png"></center>
-
<img src="https://static.igem.org/mediawiki/2012/7/75/TheoryResults.png"><br/><br/>
 
-
</div>
 
-
<div id="data3" style="display:none">
 
-
<center><h2>mCherry Fluorescence Data</h2></center><br/>
+
<center><font size="3"><b>Vivosynth Technologies: Value Proposition</b></font><br></center>
 +
<br><br>
-
<img src="https://static.igem.org/mediawiki/2012/f/f3/NEWmcherry.png" height=100% width=100%>
 
-
<br/><br/>
 
-
In order to facilitate more reliable results, we also tested our constructs with the expression of an RFP, mCherry. If in the case that confounding factors influenced our results in our experiments using YFP, we could minimize inaccurate influences on our data by using a different reporter. <br/><br/>
 
-
 
-
As of now, we are still running more mcherry experiments. The data showed some preliminary results.
 
-
The results confirmed our hypothesis that PUF-PIN don’t silence the gene from the control construct. This confirms our hypothesis that PUF-PIN doesn't silence the gene from the control construct.
 
-
 
-
</div>
 
-
 
-
<div id="data4" style="display:none">
 
-
<center><h2>Conclusion</h2></center><br/>
 
-
<p>The YFP fluorescence data has shown that the PUF-PIN domain has the ability to silence YFP expression. However, YFP expression was silenced regardless of the binding site type present in the YFP expression constructs. Assessing the specificity of PUF requires further experimental research. The mCherry data suggests that it is likely due to a problem with the YFP reporter, but due to the fact that there was no control binding site cloned into the mCherry expression construct, more experiments will be required for conclusive evidence. The specificity and customizability of our gene silencing through RNA scission both have extensive ongoing experiments.</p>
 
-
</div>
 
-
 
-
</div>
 
-
</div>
 
-
<!--END iGEM 2012 CODE-->
 
 +
<center><img src="https://static.igem.org/mediawiki/2013/c/c2/Uiuce_Capture2.PNG" width="720" height="294" alt="Pills" /></center>
<!--footer-->
<!--footer-->

Latest revision as of 03:53, 29 October 2013

Business Model
Business Overview

Customer Problem


The cloning process consists of several individual steps, each with its own equipment and machinery. It is complex, yet still requires a remarkable amount of human intervention. This results in errors, inconsistencies, and an overall delay in meeting significant synthetic biology milestones. Our team seeks to minimize this “human intervention” element by designing, prototyping, and commercializing an automated cloning system.


Pills


Our Solution


Our flagship product, ModuLab, is an automated system designed to optimize cloning, the underlying process of synthetic biology. The ultimate goals of ModuLab are to minimize error, maximize efficiency and provide synthetic biologists with feedback on every stage of the cloning process.




Competitive Analysis

Direct Competition


Because of the relative youth of synthetic biology, there are currently no products that are able to fully conduct the cloning protocol from start to finish without human intervention. We could, however, experience competition from device manufacturers that produce some of the individual components of our system. As per our own research, the closest product to ModuLab is the Freedom EVO® Expression Workstation produced by Tecan Group Ltd.

Pills

Indirect Competition

Indirect competition to the field of synthetic biology as a whole is high, given other technologies that have been around for decades. In the specific niche market within which Vivosynth is positioned, however, such competition is negligible, because of the relative nonexistence of methods to fully automate the cloning protocol.


Future Competition

Future competition will likely come in the form of new advances in robotics and automation that will further optimize cloning. Vivosynth is uniquely suited to adapting to these new advances because of our close ties to the University of Illinois and our ability to modify our product(s) as and when it needs


Competitive Advantage


Our product, ModuLab, would be unique in its ability to conduct the entire cloning protocol from start to finish without human intervention. As far as we know, there are no products capable of doing this. We believe such a product would dramatically increase the rate at which synthetic biology research and manufacturing progresses over the next decade. The product is also unique because it will be able to adapt to automate any lab machinery.



Market Analysis

Industry Profile


The global synthetic biology market is estimated to grow to $4.5 billion over the next three years. This is due to major developments in biomedicine, pharmaceutical drug synthesis, energy and environmental research, biomaterials, nanotechnology, and biosecurity. There have been significant investments in the industry by companies such as Amyris Inc, GeneScript, Bayer, and Blue Heron Biotechnologies. Additionally, developments in DNA synthesis and sequencing technologies and bioinformatics have catalyzed the progress of synthetic biology ever since the creation of the first synthetic cell in 2010. Synthetic biology is being recognized around the world as an emerging technology that has the potential to provide solutions to energy and food shortage, pollution, infectious diseases, and even climate change. The following diagram depicts the distribution of the global synthetic biology market share, as of 2011:



Pills

Marketing Strategy

Vivosynth will adopt a two-step marketing plan for commercializing ModuLab. It involves the systematic dissemination of our technologies to academic and research institutions at highly discounted rates, followed by the targeted selection of pharmaceutical companies and chemical manufacturers with our final full-price system. Intellectual property protection for our design will be obtained prior to the execution of our sales strategy.

Next, the company will look to enter into distribution agreements for the registration and sales of its products in the United States, and eventually foreign countries. These distribution agreements will take the form of contracts with existing manufacturers of biotechnology devices, in order to achieve economies of scale.

Vivosynth will also actively pursue online advertising, advertise our products at biotechnology oriented trade shows, and release a monthly newsletter to keep potential and current customers updated about product developments.

Pills



Past and Projected Timeline

Our business model has currently been implemented through the model creation phase. Next steps include cultivating relationships and licensing our technology to existing biotechnology device manufacturers.

Pills




Financial Plan


Vivosynth Technologies: Value Proposition


Pills

Retrieved from "http://2013.igem.org/Uiuce_bus_model"